Reordering the pecking order: management describes the company winning on a stage where it used to be too small to play
The model's full reasoning — Q4 2023 call → NOWe need to determine if management describes the company as now competing and winning at a level of the market that used to be above it. The key is a change in tier, already real, and early. Looking at the transcript: The company is CollPlant, a biotech developing collagen-based products. They have a partnership with AbbVie for a dermal filler. They also have breast implants, etc. Management discusses their progress. They mention that they achieved a milestone with AbbVie that triggered a $10 million payment. They also mention that they have a photocurable dermal filler product candidate, and they received a patent. They also mention that they have a right of first negotiation for AbbVie for that product. But does management describe a change in tier? They are a small biotech partnering with a large pharma (AbbVie). That could be seen as moving up a tier. However, the question is about competing and winning at a level that used to be above them. The partnership with AbbVie is a collaboration, not necessarily winning business against rivals. They are developing a product with AbbVie, which is a major player. But is that a change in tier? They were already in a partnership with AbbVie before? Actually, the transcript says "the dermal filler product candidate that we are partnering with Avion, specifically its Allergan division" - that's AbbVie's Allergan. They have been partnering for a while. The milestone payment is a result of progress, not a new tier. Management also discusses breast implants, large animal studies, etc. They mention that they are developing regenerative breast implants, which could be a new market. But they don't describe winning business or being considered at a higher level. They also mention that they put gut-on-a-chip on hold. The question is specifically about whether management conveys that the company has recently begun to be treated as a legitimate contender in situations that previously would have gone to bigger players, and that this has already produced real results. In the transcript, management talks about their collaboration with AbbVie, but that's an existing partnership. They also talk about a patent for photocurable dermal filler, and a notice of allowance in Brazil. But that's not about winning business. They also mention that they are working with Stratasys on bioprinting. That's a collaboration.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
PRIM · Q2 2018 → YESThe question is: Does management describe that the company is NOW COMPETING AND WINNING AT A LEVEL OF THE MARKET THAT USED TO BE ABOVE IT? YES The transcript shows management describing exactly this tier shift in the T&D segment: after the Willbros acquisition, the group “has been able to sign new awards with customers that have been hesitant because of previous concerns about their financial viability” and has received work from “some of the largest electrical utilities in the country.” David King notes that the work “outpaces anything he has seen in his 40-plus years,” and Pete Moerbeek adds that the one-year MSA revenue alone is now $1.1 million. Management presents these wins as a direct result of Primoris’s financial strength and parent-company backing, which previously excluded the T&D business from the largest accounts. The commentary frames the development as newly enabled and still early (only one month of T&D performance), satisfying all three required elements: a clear change in competitive tier, real business already won, and contribution still incremental relative to the company’s prior scale.
SANG · Q2 2024 → YESThe question is: Does management describe that the company is NOW COMPETING AND WINNING AT A LEVEL OF THE MARKET THAT USED TO BE ABOVE IT? YES The transcript shows management describing a shift to competing at a higher tier with sophisticated mid-market clients through bundled offerings, illustrated by a recent win with a statewide park department that larger vendors couldn't serve affordably. They explicitly note this represents a change in tier ("the type of client the bundled capabilities of Sangoma can reach ... Sangoma is well positioned to play in both the small market and more sophisticated mid-market") and that it has already produced real results ("this recent win"), while conveying it is early ("there'll be a lag before it delivers material results.
WD · Q2 2022 → YESThe question is: Does management describe that the company is NOW COMPETING AND WINNING AT A LEVEL OF THE MARKET THAT USED TO BE ABOVE IT? YES The transcript shows management explicitly describing a tier shift: from competing "predominantly with the likes of JPMorgan and Wells Fargo" to "going head-to-head with CBRE and JLL," enabled by technology investments that now allow them to "successfully compete against these much larger firms.